IMMUNOGEN INC. overview

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”) approved, effective as of July 31, 2023, grants of non-qualified stock options to purchase an aggregate of 20,600 shares of its common stock and restricted stock units (“RSUs”) covering 10,300 shares of its common stock under the Inducement Plan...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer, is stepping down from her position with the Company to take a well-deserved professional hiatus prior to pursuing new opportunities outside of ImmunoGen. Dr. Berkenblit will continue with the Company through the end of August to support the transition of her responsibilities....

ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2023. “This quarter we achieved a significant milestone for patients and our organization. With positive data from our confirmatory MIRASOL trial, ELAHERE is the first therapy to demonstrate an overall survival benefit versus chemotherapy in a Phase 3 trial in...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will participate in a fireside chat at the upcoming Canaccord Genuity 43 rd Annual Growth Conference in Boston, MA. The presentation is scheduled for August 10, 2023 at 10:00 am ET. A webcast of the presentation will be accessible through the “Investors and Media” section of the Company’s website, www.immunogen.com . Following the...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel biological therapeutics. The collaboration will combine ImmunoGen's proprietary linker-payload technology with...

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Monday, July 31, 2023 to discuss its second quarter 2023 operating results. Management will also provide a brief update on the business. CONFERENCE CALL INFORMATION To access the live call by phone, please register here . A dial-in and unique PIN will be provided to join the call. The call...

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”) approved, effective as of June 30, 2023, grants of non-qualified stock options to purchase 32,300 shares of its common stock and restricted stock units (“RSUs”) covering 16,150 shares of its common stock under the Inducement Plan to three new...

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced updated data from an interim analysis of the Phase 2 CADENZA trial of pivekimab sunirine (pivekimab) in patients with frontline and relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN). The data will be presented in an oral session on Sunday, June 11 at the European Hematology Association (EHA) 2023 Congress in Frankfurt,...